Published :
Tables : 46
Figures : 42
Category : Healthcare
No. of Pages : 219
Report Code : HC-U9322
Antidiabetics Market Overview: Anti-diabetics medicines are also known as oral hypoglycemic/antihyperglycemic therapies and are used to treat diabetes mellitus. With the rising frequency of diabetes mellitus, the anti-diabetics industry has exploded in recent years.. Global diabetes patient is expected to rise from 366 million in 2011 to 552 million by 2030, according to the International Diabetes Federation. The market is likely to benefit in the future as a result of the huge increase of diabetic patients. Other factors such as the ageing population, rising obesity cases, and the development of new products with diabetes affecting middle age groups and children across all income levels worldwide are projected to help the market throughout the forecast period. Furthermore, the increased approval of antidiabetic medications, as well as a robust pool of antidiabetic drugs, are likely to provide considerable market expansion potential. SCO-094, Tirzepatide, Volagidemab, CT-388, GX G6, ORMD-0801, and more antidiabetic drugs are in the pipeline. Also, the growing number of FDA drug approvals is expected to provide considerable prospects for the players. The number of treatment options for T2DM is growing, with the FDA having authorised roughly 60 medications. A total of about 100 new anti-diabetic drugs are currently being tested in clinical studies. There are also new medication combinations comprising metformin, SGLT2 inhibitors, and dipeptidyl peptidase-4, in addition to the traditional treatments of insulin therapy and metformin (DPP4). Type 2 diabetes is becoming more common as people become older, as is the risk of vascular disease, coronary heart disease, and stroke. As a result, the market is likely to profit in the forecast period as a result of the need to control comorbidities . FutureWise Market Research has instantiated a report that provides an intricate analysis of Antidiabetics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Antidiabetics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Antidiabetics Market: • AstraZeneca • Bayer Corporation • Boehringer Ingelheim • Bristol-Myers Squibb. • Eli Lilly. • Halozyme Therapeutics • Johnson & Johnson • Merck & Co. Inc. • Novartis AG • Novo Nordisk • Oramed Pharmaceuticals Inc. • Pfizer • Sanofi • Takeda Pharmaceutical (Note: The list of the major players will be updated with the latest market scenario and trends) Antidiabetics Market Segmentation: By Product • Insulin-based Antidiabetics o Rapid-Acting Analog o Long-Acting Analog o Premixed Insulin o Short-Acting Analog o Intermediate-Acting Insulin • Antidiabetics Drug Class o Alpha-Glucosidases Inhibitors o Biguanides o Sulphonylureas o GLP-1 (Glucagon-like peptide) Agonists o DPP-IV (Dipeptidyl Peptidase) Inhibitors o Meglitinides o SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors o Thiazolidinedione By Patient Population • Pediatrics • Adults • Geriatrics By Route of Administration • Insulin Syringes/ Insulin Pens • Insulin Pumps • Intravenous Infusion • Oral • Other Routes By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Antidiabetics Market By Product, By Patient Population, By Route of Administration and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Anti-diabetics medicines are also known as oral hypoglycemic/antihyperglycemic therapies and are used to treat diabetes mellitus. With the rising frequency of diabetes mellitus, the anti-diabetics industry has exploded in recent years.. Global diabetes patient is expected to rise from 366 million in 2011 to 552 million by 2030, according to the International Diabetes Federation. The market is likely to benefit in the future as a result of the huge increase of diabetic patients. Other factors such as the ageing population, rising obesity cases, and the development of new products with diabetes affecting middle age groups and children across all income levels worldwide are projected to help the market throughout the forecast period. Furthermore, the increased approval of antidiabetic medications, as well as a robust pool of antidiabetic drugs, are likely to provide considerable market expansion potential. SCO-094, Tirzepatide, Volagidemab, CT-388, GX G6, ORMD-0801, and more antidiabetic drugs are in the pipeline. Also, the growing number of FDA drug approvals is expected to provide considerable prospects for the players. The number of treatment options for T2DM is growing, with the FDA having authorised roughly 60 medications. A total of about 100 new anti-diabetic drugs are currently being tested in clinical studies. There are also new medication combinations comprising metformin, SGLT2 inhibitors, and dipeptidyl peptidase-4, in addition to the traditional treatments of insulin therapy and metformin (DPP4). Type 2 diabetes is becoming more common as people become older, as is the risk of vascular disease, coronary heart disease, and stroke. As a result, the market is likely to profit in the forecast period as a result of the need to control comorbidities .
FutureWise Market Research has instantiated a report that provides an intricate analysis of Antidiabetics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Antidiabetics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Antidiabetics Market: • AstraZeneca • Bayer Corporation • Boehringer Ingelheim • Bristol-Myers Squibb. • Eli Lilly. • Halozyme Therapeutics • Johnson & Johnson • Merck & Co. Inc. • Novartis AG • Novo Nordisk • Oramed Pharmaceuticals Inc. • Pfizer • Sanofi • Takeda Pharmaceutical (Note: The list of the major players will be updated with the latest market scenario and trends)
Antidiabetics Market Segmentation: By Product • Insulin-based Antidiabetics o Rapid-Acting Analog o Long-Acting Analog o Premixed Insulin o Short-Acting Analog o Intermediate-Acting Insulin • Antidiabetics Drug Class o Alpha-Glucosidases Inhibitors o Biguanides o Sulphonylureas o GLP-1 (Glucagon-like peptide) Agonists o DPP-IV (Dipeptidyl Peptidase) Inhibitors o Meglitinides o SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors o Thiazolidinedione By Patient Population • Pediatrics • Adults • Geriatrics By Route of Administration • Insulin Syringes/ Insulin Pens • Insulin Pumps • Intravenous Infusion • Oral • Other Routes By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Antidiabetics Market By Product, By Patient Population, By Route of Administration and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Antidiabetics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Antidiabetics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Antidiabetics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Antidiabetics Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Insulin-based Antidiabetics 7.1.1. Rapid-Acting Analog 7.1.2. Long-Acting Analog 7.1.3. Premixed Insulin 7.1.4. Short-Acting Analog 7.1.5. Intermediate-Acting Insulin 7.2. Antidiabetics Drug Class 7.2.1. Alpha-Glucosidases Inhibitors 7.2.2. Biguanides 7.2.3. Sulphonylureas 7.2.4. GLP-1 (Glucagon-like peptide) Agonists 7.2.5. DPP-IV (Dipeptidyl Peptidase) Inhibitors 7.2.6. Meglitinides 7.2.7. SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors 7.2.8. Thiazolidinedione 8. Antidiabetics Market, By Patient Population Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Pediatrics 8.2. Adults 8.3. Geriatrics 9. Antidiabetics Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Insulin Syringes/ Insulin Pens 9.2. Insulin Pumps 9.3. Intravenous Infusion 9.4. Oral 9.5. Other Routes 10. North America Antidiabetics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Antidiabetics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Antidiabetics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Antidiabetics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. AstraZeneca 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Bayer Corporation 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Boehringer Ingelheim 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Bristol-Myers Squibb. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Eli Lilly. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Halozyme Therapeutics 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Johnson & Johnson 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Merck & Co. Inc. 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Novartis AG 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Novo Nordisk 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.Oramed Pharmaceuticals Inc. 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Pfizer 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.Sanofi 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14.Takeda Pharmaceutical 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics